Cardiff Oncology will present new preclinical data on onvansertib's effectiveness with T-DXd at the AACR Annual Meeting 2026.
Quiver AI Summary
Cardiff Oncology, Inc. announced new preclinical findings regarding its oral PLK1 inhibitor, onvansertib, which will be presented at the American Association for Cancer Research Annual Meeting 2026. The research highlights onvansertib's ability to enhance the effectiveness of trastuzumab deruxtecan (T-DXd) and to overcome resistance in HER2-low breast cancer models. The poster presentation is scheduled for April 19, 2026. Onvansertib is currently in mid-stage clinical trials for RAS-mutated metastatic colorectal cancer and is also being investigated in other cancer types. Cardiff Oncology focuses on innovative cancer treatment strategies targeting PLK1, aiming to address significant patient needs and improve treatment outcomes.
Potential Positives
- Presentation of new preclinical data at the prominent American Association for Cancer Research Annual Meeting showcases the potential of onvansertib in enhancing the effectiveness of trastuzumab deruxtecan, a significant combination for cancer treatment.
- The findings indicate that onvansertib can reverse resistance in therapy-resistant HER2-low breast cancer models, which highlights its potential to address unmet medical needs in this patient population.
- Onvansertib's evaluation across multiple cancer types and its advanced development stage signal the company’s commitment to innovation in oncology, enhancing its reputation in the biotech sector.
- The upcoming poster presentation at a major conference provides visibility for the company and its product pipeline, potentially attracting interest from investors and collaborators.
Potential Negatives
- Although the presentation of new preclinical data is a positive development, the fact that onvansertib is still in mid-stage clinical development suggests that the company may not have any products ready for market, which could impact investor confidence.
- The focus on therapy-resistant cancer models implies that existing therapies are failing, which may raise concerns about the effectiveness of current cancer treatments and the urgent need for new solutions.
- While onvansertib shows promise in combination with trastuzumab deruxtecan, the reliance on early-stage data can lead to over-promising results that may not translate into clinical success, potentially misleading stakeholders about the drug's future prospects.
FAQ
What is onvansertib?
Onvansertib is a highly specific oral PLK1 inhibitor in clinical development for various cancer types, including RAS-mutated metastatic colorectal cancer.
When will the new data on onvansertib be presented?
The new preclinical data on onvansertib will be presented at the AACR Annual Meeting from April 17-22, 2026.
What cancers is onvansertib targeting?
Onvansertib is being evaluated for RAS-mutated metastatic colorectal cancer and several other cancers, including breast and pancreatic cancers.
How does onvansertib affect trastuzumab deruxtecan?
Onvansertib enhances the antitumor activity of trastuzumab deruxtecan and reverses resistance in therapy-resistant HER2-low breast cancer models.
Where can I find the poster presentation details?
The poster presentation details will be available on the Scientific Publications page of Cardiff Oncology's website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRDF Hedge Fund Activity
We have seen 44 institutional investors add shares of $CRDF stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,423,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,931,380
- FRANKLIN RESOURCES INC added 1,205,803 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,388,306
- TWO SIGMA INVESTMENTS, LP added 520,947 shares (+255.4%) to their portfolio in Q4 2025, for an estimated $1,463,861
- CANDRIAM S.C.A. added 344,437 shares (+inf%) to their portfolio in Q4 2025, for an estimated $967,867
- TWO SIGMA ADVISERS, LP added 334,700 shares (+1297.3%) to their portfolio in Q4 2025, for an estimated $940,507
- MARSHALL WACE, LLP removed 298,715 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $615,352
- BLAIR WILLIAM & CO/IL removed 264,759 shares (-12.0%) from their portfolio in Q4 2025, for an estimated $743,972
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRDF Price Targets
Multiple analysts have issued price targets for $CRDF recently. We have seen 2 analysts offer price targets for $CRDF in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $6.0 on 02/25/2026
- Robert Burns from HC Wainwright & Co. set a target price of $10.0 on 01/28/2026
Full Release
SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low breast cancer models.
Poster Presentation Details:
- Title: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models
- Date & Time: April 19, 2026 | 2:00 PM – 5:00 PM PT
-
Abstract Number:
329
The poster will be made available on the Scientific Publications page of the Company’s website following the presentation.
About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com .
Investor Contact:
Candice Masse
astr partners
[email protected]
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]
